XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Income Statement [Abstract]        
Sales $ 16,112 $ 15,035 $ 31,887 $ 29,522
Costs, Expenses and Other        
Cost of sales 3,745 4,024 7,285 7,951
Selling, general and administrative 2,739 2,702 5,221 5,182
Research and development 3,500 13,321 7,492 17,597
Restructuring costs 80 151 202 218
Other (income) expense, net 42 172 12 259
Total Costs, Expenses and Other 10,106 20,370 20,212 31,207
Income (Loss) Before Taxes 6,006 (5,335) 11,675 (1,685)
Income Tax Provision 545 637 1,447 1,462
Net Income (Loss) 5,461 (5,972) 10,228 (3,147)
Less: Net Income Attributable to Noncontrolling Interests 6 3 11 7
Net Income (Loss) Attributable to Merck & Co., Inc. $ 5,455 $ (5,975) $ 10,217 $ (3,154)
Basic Earnings (Loss) per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) $ 2.15 $ (2.35) $ 4.03 $ (1.24)
Earnings (Loss) per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) $ 2.14 $ (2.35) $ 4.02 $ (1.24)